HOW GLP-1 IS INFLUENCING FOOD INNOVATION
While GLP-1 was initially confined to the medical sphere, its growing visibility is now influencing food innovation, product development and consumer expectations. For food companies and brands, the phenomenon highlights a broader transformation in how consumers approach eating: fewer calories, higher nutritional density and a stronger focus on wellbeing.
For professionals attending international food industry trade shows such as SIAL Paris, the emergence of GLP-1 related trends illustrates how medical research, consumer lifestyles and product innovation increasingly intersect.
Understanding GLP-1 and its influence on appetite
GLP-1 (Glucagon-Like Peptide-1) is a hormone naturally produced in the body, primarily by cells in the intestine after food consumption. It plays an important role in several physiological processes linked to digestion and metabolism.
Among its key effects, GLP-1 contributes to reducing appetite, slowing gastric emptying and improving blood sugar regulation. These mechanisms explain why GLP-1 has become central in treatments for type 2 diabetes and more recently in therapies addressing obesity.
Medical analogues have been developed to replicate the action of this hormone. Treatments such as Ozempic, originally designed for diabetes management, and Wegovy, prescribed for obesity under medical supervision, mimic the body’s natural GLP-1 activity to help regulate appetite and support weight loss.
Although these medications remain strictly regulated and accessible only through medical prescription, their growing popularity has generated significant public attention. As a result, the concept of appetite regulation has moved beyond the medical field and entered the broader conversation around food consumption and nutrition.
A trend amplified by social media and public awareness
The rise of GLP-1 treatments has been accelerated by the influence of social media platforms, where discussions around weight management and health have become highly visible.
Thousands of posts on platforms such as TikTok and Instagram have documented personal experiences with GLP-1 related treatments, often highlighting rapid weight loss. Between July 2021 and April 2024, more than 850,000 online posts referenced semaglutide, the active compound used in several GLP-1 medications.
This online visibility has contributed to turning GLP-1 into a widely discussed topic beyond healthcare circles. Surveys in the United States suggest that around 12% of Americans have used GLP-1 analogues for aesthetic purposes, despite these treatments being designed for medical conditions such as obesity.
As awareness spreads, the conversation increasingly shifts towards dietary habits, nutritional balance and food choices, creating new expectations for the food industry.
Changing consumption patterns
One of the most notable consequences of GLP-1 treatments is the reduction in overall appetite. Many users report eating smaller portions and losing interest in foods that are highly processed, sugary or rich in fats.
This shift is significant for food manufacturers because it alters traditional consumption patterns. Rather than prioritising quantity, consumers increasingly seek nutrient-dense products that deliver satiety, energy and nutritional value in smaller servings.
In response, food brands are adapting their strategies by focusing on products that align with these new behaviours. Key categories gaining attention include high-protein foods, fibre-rich ingredients and functional nutrition products designed to support digestion and metabolic health.
Protein in particular has become a central focus. Since weight loss linked to GLP-1 treatments can involve a reduction in lean muscle mass, maintaining adequate protein intake is considered essential. This has led to growing demand for protein-rich meals, snacks and beverages.
Products such as protein-enriched ready meals, plant-based pasta made from legumes and high-protein nutritional drinks illustrate how manufacturers are responding to evolving consumer needs.
The emergence of “GLP-1 friendly” products
Another notable development is the appearance of products marketed as “GLP-1 friendly”. These foods typically highlight specific nutritional characteristics such as high protein content, increased fibre and reduced levels of sugar and fat.
While the label reflects a growing consumer interest in foods compatible with appetite regulation and weight management, it is important to note that there is currently no official regulatory framework governing the use of the term, particularly in the United States.
As a result, the designation remains largely a marketing concept rather than a medically recognised claim. Nevertheless, its emergence demonstrates how quickly the food industry responds to shifts in consumer perception and emerging health narratives.
Supporting natural GLP-1 production through food
Beyond pharmaceutical treatments, some brands are exploring products designed to support the body’s natural production of GLP-1.
This approach aligns with the broader trend towards functional nutrition, where foods are positioned not only as sources of nourishment but also as contributors to overall health and wellbeing.
Certain ingredients, particularly dietary fibres and prebiotics, are being promoted for their potential role in supporting digestive processes and metabolic balance. By encouraging satiety and supporting gut health, these products reflect a preventive approach to nutrition rather than a therapeutic one.
This shift resonates with growing consumer interest in natural health solutions and balanced diets, reinforcing the idea that nutrition and lifestyle remain central to long-term wellbeing.
Regulation and public health considerations
Despite the enthusiasm surrounding GLP-1 treatments, their use remains tightly regulated. These medications are not available in supermarkets and can only be prescribed by medical professionals under specific conditions.
In France, GLP-1 treatments for obesity were authorised from October 2024, initially with prescriptions restricted to specialist physicians. Since June 2025, general practitioners have also been allowed to prescribe these treatments, making them more accessible to patients.
Public health authorities emphasise that GLP-1 medications should be used only as part of a broader medical approach, including nutritional guidance and physical activity.
Experts also highlight that these treatments are not a universal solution. Studies indicate that approximately 65% of the weight lost during treatment may return within a year after discontinuation, illustrating the importance of long-term lifestyle changes.
A new horizon for food innovation
For the global food industry, the rise of GLP-1 represents more than a pharmaceutical trend. It reflects a broader shift in how consumers think about food, health and personal wellbeing.
As appetite regulation becomes part of everyday discussions, food companies are increasingly challenged to design products that are nutritionally efficient, satisfying and aligned with evolving health expectations.
For professionals gathering at SIAL Paris, this transformation highlights the importance of innovation that goes beyond flavour or convenience. The next generation of food products will likely combine nutritional science, consumer insight and culinary creativity, responding to a market where health considerations are becoming inseparable from food choices.
In this context, GLP-1 may not represent a revolution in itself, but rather a catalyst for a deeper transformation within the food ecosystem. It illustrates how medical research, lifestyle trends and product innovation are converging to shape the future of global food consumption.